- $2.49bn
- $1.84bn
- $8.08m
- 53
- 16
- 75
- 46
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.79 | ||
| Price to Tang. Book | 3.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 341.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -10.74% | ||
| Return on Equity | -11.5% | ||
| Operating Margin | -999.85% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 3.64 | 8.61 | 8.08 | 3.17 | 2.04 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Directors
- Jay Lichter CHM (59)
- David Campbell PRE (62)
- Tighe Reardon CFO (45)
- Andy Meyer EXO (37)
- Tommy Diraimondo OTH
- Neil Gibson OTH
- Marc Nasoff OTH
- Ronald Barrett DRC
- Sheila Gujrathi DRC
- Alana Mcnulty DRC
- Vickie Capps IND (59)
- Stefan Heller IND (55)
- Jake Simson IND (35)
- Peter Thompson IND (61)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- June 27th, 2017
- Public Since
- June 11th, 2021
- No. of Shareholders
- 24
- No. of Employees
- 64
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 51,850,667
- Address
- 10955 Vista Sorrento Parkway, Suite 200, SAN DIEGO, 92130
- Web
- https://www.januxrx.com/
- Phone
- +1 8587514493
- Auditors
- Ernst & Young LLP
Upcoming Events for JANX
Q2 2024 Janux Therapeutics Inc Earnings Release
Similar to JANX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Janux Therapeutics share price?
As of Today at 16:07 UTC, shares in Janux Therapeutics are trading at $47.99. This share price information is delayed by 15 minutes.
How has the Janux Therapeutics share price performed this year?
Shares in Janux Therapeutics last closed at $47.99 and the price had moved by +259.21% over the past 365 days. In terms of relative price strength the Janux Therapeutics share price has outperformed the S&P500 Index by +183.72% over the past year.
What are the analyst and broker recommendations for Janux Therapeutics?
The overall consensus recommendation for Janux Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Janux Therapeutics dividend yield?
Janux Therapeutics does not currently pay a dividend.
Does Janux Therapeutics pay a dividend?
Janux Therapeutics does not currently pay a dividend.
When does Janux Therapeutics next pay dividends?
Janux Therapeutics does not currently pay a dividend.
How do I buy Janux Therapeutics shares?
To buy shares in Janux Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Janux Therapeutics?
As of the previous close price of $47.99, shares in Janux Therapeutics had a market capitalisation of $2.49bn.
Where are Janux Therapeutics shares listed?
Here are the trading details for Janux Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: JANX
What kind of share is Janux Therapeutics?
Based on an overall assessment of its quality, value and momentum Janux Therapeutics is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Janux Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Janux Therapeutics is $65.43. That is 36.34% above the last closing price of $47.99.
Analysts covering Janux Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.32 for the next financial year.
What is the trend in the Janux Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Janux Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +352.47%.
As of the last closing price of $47.99, shares in Janux Therapeutics were trading +135.83% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Janux Therapeutics PE Ratio?
The Janux Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $47.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Janux Therapeutics?
Janux Therapeutics' management team is headed by:
- Jay Lichter - CHM
- David Campbell - PRE
- Tighe Reardon - CFO
- Andy Meyer - EXO
- Tommy Diraimondo - OTH
- Neil Gibson - OTH
- Marc Nasoff - OTH
- Ronald Barrett - DRC
- Sheila Gujrathi - DRC
- Alana Mcnulty - DRC
- Vickie Capps - IND
- Stefan Heller - IND
- Jake Simson - IND
- Peter Thompson - IND